Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice

Pharmacology

Volumn 87, Issue 1-2, 2011, Pages 105-114

  Ying, Xue ^a,b   Wen, He ^a   Yao, Hong Juan ^a   Zhang, Yan ^a   Tian, Wei ^a   Zhang, Liang ^a   Ju, Rui Jun ^a   Wang, Xiao Xing ^a   Yu, Yang ^a   Lu, Wan Liang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHIHEZI UNIVERSITY   (China)

Author keywords

Dual targeting daunorubicin liposomes; HPLC; Pharmacokinetics; Tissue distribution

Indexed keywords

DAUNORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CIRCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TRANSPORT; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PARENCHYMA; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SPLEEN; TISSUE DISTRIBUTION; ULTRAVIOLET SPECTROSCOPY;

ANILINE COMPOUNDS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; HALF-LIFE; LIPOSOMES; MALE; MANNOSIDES; METABOLIC CLEARANCE RATE; MICE; MYOCARDIUM; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 79251570574     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323222     Document Type: Article

References (27)

1. Pardridge WM: BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today 2001; 6: 381-383. (Pubitemid 32328285)
2. 2010; 141: 183-192.
3. Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF: Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta 2010; 1806: 96-107.
4. Alves OL, Doyle AJ, Clausen T, Gilman C, Bullock R: Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann NY Acad Sci 2003; 993: 25-34. (Pubitemid 36808429)
5. Zhang C, Ping QN, Zhang HG, Shen J: Preparation of N-alkyl-O-sulfate chitosan derivatives and micellar solubilization of Taxol. Carbohydr Polym 2003; 54: 137-141.
6. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A: In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 2009;236: 97-108.
7. Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H: Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008; 29: 1233-1241.
8. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741. (Pubitemid 29094544)
9. Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, Tseng YL, Hong K, Kirpotin DB: Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther 2009; 328: 321-330.
10. 2008; 126: 162-165.
11. Ishida T, Kiwada H: Accelerated blood clearance (ABC) phenomenon upon repeated injection of pegylated liposomes. Int J Pharm 2008; 354: 56-62.
12. Blume G, Cevc G: Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990; 1029: 91-97. (Pubitemid 20346426)
13. Klibanov AL, Maruyama K, Torchilin VP, Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235-237. (Pubitemid 20233874)
14. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066: 29-36.
15. Lotfi K, Zackrisson AL, Peterson C: Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 2002; 178: 141-149. (Pubitemid 34178538)
16. Danesi R, Paparelli A, Bernardini N, Del Tacca M: Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur J Cancer Clin Oncol 1988; 24: 1123-1131.
17. Averbuch SD, Glover CJ, Felsted RL: Anthracycline photoaffinity labeling of a mitochondrial polypeptide in P388 murine leukemic cell lines. Cancer Res 1986; 46: 6120-6124. (Pubitemid 17221741)
18. ONS Clinical Practice Committee: Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, Oncology Nursing Society, 1999, pp 32-41.
19. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-3131.
20. Nishiyama N, Kataoka K: Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006; 112: 630-648. (Pubitemid 44592613)
21. Paul C, Baurain R, Gahrton G, Peterson C: Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. Cancer Lett 1980; 9: 263-269. (Pubitemid 10047695)
22. ElBayoumi TA, Torchilin VP: Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, longcirculating liposomes modified with cancerspecific monoclonal antibody. Clin Cancer Res 2009; 15: 1973-1980.
23. 2006; 1: 297-315.
24. Allison SD: Liposomal drug delivery. J Infus Nurs 2007; 30: 89-95. (Pubitemid 46579957)
25. 2009; 325: 612-616.
26. Patel HM: Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 1992; 9: 39-90.
27. Daunorubicin official FDA information. http://www.drugs.com/pro/ daunorubicin. html.